Lingyi Biotechnology

About Lingyi Biotechnology

Lingyi Biotechnology, also known as Lingyi (Hangzhou) Biotechnology Co., Ltd., is a clinical-stage biotechnology company established in February 2021. The company was founded by Dr. Andrew Lin (Lin Qing), a molecular geneticist and former Principal Investigator at Vanderbilt University, who currently serves as the CEO. Based in Shanghai and Hangzhou, China, Lingyi Biotechnology is focused on developing next-generation Adeno-Associated Virus (AAV) gene therapies to treat monogenic and rare genetic diseases.

The company's core technology is its proprietary AAV2.0 platform, a precision gene therapy system designed for improved, tissue- and cell-specific delivery and transduction with a regulatable cargo design. This platform is complemented by a rare disease animal model functional validation platform, which is central to its research and development process. Lingyi targets clinically urgent areas such as metabolic disorders, central nervous system (CNS) conditions, and ophthalmic diseases. A key product in their pipeline is the LY-M001 injection, a gene therapy for Gaucher disease that utilizes a recombinant AAV to deliver a modified glucocerebrosidase gene. This product has received Investigational New Drug (IND) approval from both the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA).

Lingyi Biotechnology operates on a B2B2C model, aiming for commercial scaling through strategic partnerships and a dual-market regulatory strategy in China and the United States. In February 2022, the company secured an undisclosed amount in a Seed funding round from investors including Matrix Partners China. The company has also entered into a strategic partnership with Zhejiang Zuoli Pharmaceutical to facilitate the commercialization of its gene therapies in global markets. Lingyi's business strategy emphasizes original innovation and aims to provide safer, more effective, and accessible treatment options for patients with rare genetic disorders.